SG Americas Securities LLC acquired a new position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 94,269 shares of the biotechnology company’s stock, valued at approximately $1,301,000. SG Americas Securities LLC owned about 0.45% of Aldeyra Therapeutics as of its most recent SEC filing.
Other large investors have also recently made changes to their positions in the company. Rhumbline Advisers purchased a new position in shares of Aldeyra Therapeutics in the second quarter worth about $113,000. Schwab Charles Investment Management Inc. purchased a new position in shares of Aldeyra Therapeutics in the second quarter worth about $237,000. Bank of New York Mellon Corp raised its stake in shares of Aldeyra Therapeutics by 139.7% in the second quarter. Bank of New York Mellon Corp now owns 49,842 shares of the biotechnology company’s stock worth $396,000 after purchasing an additional 29,051 shares during the last quarter. Stanley Laman Group Ltd. raised its stake in shares of Aldeyra Therapeutics by 54.4% in the second quarter. Stanley Laman Group Ltd. now owns 98,892 shares of the biotechnology company’s stock worth $786,000 after purchasing an additional 34,863 shares during the last quarter. Finally, Russell Investments Group Ltd. purchased a new position in shares of Aldeyra Therapeutics in the second quarter worth about $1,335,000. Hedge funds and other institutional investors own 69.10% of the company’s stock.
Shares of ALDX stock opened at $9.23 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.82 and a quick ratio of 4.82. The company has a market cap of $258.51 million, a P/E ratio of -6.59 and a beta of 0.81. Aldeyra Therapeutics, Inc has a twelve month low of $6.20 and a twelve month high of $16.70.
Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings results on Wednesday, November 14th. The biotechnology company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.05). As a group, equities analysts predict that Aldeyra Therapeutics, Inc will post -1.83 earnings per share for the current year.
Several research analysts have recently issued reports on ALDX shares. Cantor Fitzgerald set a $30.00 price objective on Aldeyra Therapeutics and gave the stock a “buy” rating in a research note on Thursday, October 4th. Janney Montgomery Scott started coverage on Aldeyra Therapeutics in a research note on Thursday, September 13th. They issued a “buy” rating for the company. Canaccord Genuity restated a “buy” rating and issued a $27.00 price objective on shares of Aldeyra Therapeutics in a research note on Friday, August 10th. ValuEngine upgraded Aldeyra Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, September 20th. Finally, Citigroup started coverage on Aldeyra Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $23.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $24.64.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.
Recommended Story: Intrinsic Value and Stock Selection
Want to see what other hedge funds are holding ALDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aldeyra Therapeutics, Inc (NASDAQ:ALDX).
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.